NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition
description
Transcript of NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition
![Page 1: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/1.jpg)
NABATIVI –
Novel Approaches to Bacterial Target Identification, Validation and Inhibition
Alessandra Bragonzi, PhD
Infections and Cystic Fibrosis Unit,Division of Immunology, Transplantation and Infectious Disease San Raffaele Scientific Institute
![Page 2: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/2.jpg)
2
OUTLINE
• The problem
• Anti-microbial drug resistance
• Pharmaceutics' response
• EU’s response
• How we built the NABATIVI project
• International collaboration
• Multidisciplinary approach
• Scientific excellence
• Major achievement
![Page 3: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/3.jpg)
3
OUTLINE
• The problem
• Anti-microbial drug resistance
• Pharmaceutics' response
• EU’s response
• How we built the NABATIVI project
• International collaboration
• Multidisciplinary approach
• Scientific excellence
• Major achievement
![Page 4: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/4.jpg)
4
The world-wide threat of resistant pathogens
![Page 5: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/5.jpg)
5
What is boosting antimicrobial resistance?
5
superbugssuperbugsInsufficient surveillance, prevention and control
Insufficient research and development activities
Absence of new drugs
Insufficient funding
Insufficient coordination of EU efforts
![Page 6: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/6.jpg)
6
Why is antimicrobial resistance a global concern?
• kills
• hampers the control of infectious diseases
• threatens a return to the pre-antibiotic era
• increases the costs of health care
• jeopardizes health-care gains to society
![Page 7: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/7.jpg)
7
Facts on antimicrobial resistance
• 4 million patients every year
• 25 000 deaths
• economic losses € 1.5 billion
![Page 8: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/8.jpg)
8
Who is responsible?
Enterococcus faecium
Staphylococcus aereus
Klebsiella pneumoniae
Acinetobacter baumanni
Pseudomonas aeruginosa
Enterobacter species
![Page 9: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/9.jpg)
9
OUTLINE
• The problem
• Anti-microbial drug resistance
• Pharmaceutics' response
• EU’s response
• How we built the NABATIVI project
• International collaboration
• Multidisciplinary approach
• Scientific excellence
• Major achievement
![Page 10: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/10.jpg)
10
Pharmaceutics’ response to antimicrobial-resistance
Payne et al. Nature Reviews Drug Discovery 6, 2007
• The industry is cutting research in antimicrobial discovery and development
• Only few big pharmaceutical companies are still involved in antibiotic discovery
• Antibiotic R&D is a lengthy, costly, and risky process due to:
- length of time (10-15 years) from the discovery phase to market
- huge cost of bringing a new drug to market ($800 million to 1.7 billion)
- low reimbursement due to the small market
- low success rate
![Page 11: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/11.jpg)
11
Antibacterial pipeline, Big Pharma
Boucher H W et al. Clin Infect Dis. 2013;56:1685-1694
New systemic antibacterial agents approved by the US Food and Drug Administration per 5-year period, through 2012.
![Page 12: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/12.jpg)
12
How do we fill the gap ?
![Page 13: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/13.jpg)
13
OUTLINE
• The problem
• Anti-microbial drug resistance
• Pharmaceutics' response
• EU’s response
• How we built the NABATIVI project
• International collaboration
• Multidisciplinary approach
• Scientific excellence
• Major achievement
![Page 14: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/14.jpg)
14
EU’s response –6th and 7th Framework Programme
• Basic Science
• Prudent use of antibiotics
• New antimicrobials
• Point of care diagnostic tests
• Vaccines
![Page 15: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/15.jpg)
15
EU’s response –Translational research for health (unit F3)
• 2.3.1 – Anti-microbial drug resistance
• Management of Gram negative multi-drug resistant infections.
2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES: TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH2.3.1. Anti-microbial drug resistance including fungal pathogens
2.3.1-1: Novel targets for drugs against Gram negative bacteria.The objective is to identify and validate novel drug targets in order to select lead compounds, which may be derived from natural sources or from synthetic compounds, for future development of a new class of anti-infective drugs against Gram-negative bacteria. Significant industrial involvement, particularly by SMEs, is foreseen in this topic. Funding scheme: Collaborative projects (Small or medium-scale focused research projects with maximum EC contribution of € 6,000,000/project).
SME ≥30%
![Page 16: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/16.jpg)
16
OUTLINE
• The problem
• Anti-microbial drug resistance
• Pharmaceutics' response
• EU’s response
• How we built the NABATIVI project
• International collaboration
• Multidisciplinary approach
• Scientific excellence
• Major achievement
![Page 17: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/17.jpg)
17
How we built the NABATIVI project
• International Collaboration
Academic SMEs
Alessandra Bragonzi, San Raffaele Scientific Institute, Milano
Miguel Cámara, University of Nottingham
Gerd Döring, Eberhard Karls Univerität Tübingen
John A. Robinson and Leo Eberl, University of Zürich
Giovanni Bertoni, Università degli Studi di Milano
Peter E. Nielsen, University of Copenhagen
Natalia Nekohotieva, KDevExploratory, Stockholm
Do Quoc-Tuan, Greenpharma S.A., Orléans,
Daniel Obrecht, Polyphor, Allschwil
![Page 18: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/18.jpg)
18
How we built the NABATIVI project
• Multidisciplinary approach
Drugs
Molecular microbiology
Genomics
Biochemistry
Structural biology
Cell biologyBioinformatics
Clinical research
Pre-clinical research
High-throughput technology
![Page 19: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/19.jpg)
19
NABATIVI approaches in response to Call FP7-HEALTH-2007-B
19
Discovery Phase Approach A: “from target to lead compounds”•Target identification/validation is done at the beginning
Discovery Phase Approach B: “from drugs to targets”• Target identification runs in parallel to the discovery phase
Targetidentification
Libraryselection/design
Screeningcascade
Hitidentification Hit-to-lead
Leadoptimization
Pre-clinicaldevelopment Phase I Phase II Phase III NDA Launch
Pre-clinical and clinical phases
Discovery phaseA
B
![Page 20: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/20.jpg)
20
Pseudomonas aeruginosa selected from ESKAPE pathogens
• 5 million cases in Europe, USA and Japan every year
• Responsible of ≈ 30% of world-wide hospital-acquired infections
• High risk of disease in people with cystic fibrosis, in immunocompromised, burn patients, patients with cancer, and with HIV
• Multi-drug resistant strains
![Page 21: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/21.jpg)
21
Scientific approach –Genome - based approach for target identification
PAO1 6.3 Mb
5,570 ORFs
6,7% function experimentally demonstrated(Class 1)
Stover et al. Nature. 2000 Aug 31;406(6799):959-64.
![Page 22: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/22.jpg)
22
NABATIVI scientific approach –Step 1: genome-wide screening for targets identification
ScreeningsAntisense librariesTransposon libraries
Results
University of Nottingham Università degli Studi di Milano
![Page 23: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/23.jpg)
23
43
University of Nottingham San Raffaele Scientific InstituteUniversità degli Studi di Milano
Eberhard Karls Univerität TübingenSan Raffaele Scientific Institute
University of Zürich
Eberhard Karls Univerität TübingenSan Raffaele Scientific Institute
Genome-wide screening 57.360
404
27
5
NABATIVI scientific approach –Step 2: pathogenicity in different model system
![Page 24: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/24.jpg)
24
24
Genomic Target database
(GTD)
NABATIVI scientific approach –Step 3: target inhibition by high-throughput technology
![Page 25: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/25.jpg)
25
NH
NB
OO
NB
OO
NH
PNA
25
Genomic Target database
(GTD)Purified target-based HTS:
• Plant extracts (800)• Pure natural compounds (480)• Synthetic compounds (45000)• Database AMBINTER 18 M
compounds
KDevExploratory, Stockholm
Greenpharma S.A., Orléans,
Determination of the druggability of selected targets
Greenpharma S.A., Orléans,
NABATIVI scientific approach –Step 3: target inhibition by high-throughput technology
Antisense targeting of selected targets by peptide nucleic acids
University of Copenhagen
![Page 26: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/26.jpg)
NABATIVI approaches in response to Call FP7-HEALTH-2007-B
26
Targetidentification
Libraryselection/design
Screeningcascade
Hitidentification Hit-to-lead
Leadoptimization
Pre-clinicaldevelopment
Phase I Phase II Phase III NDA Launch
Synthesis of a library of Protegrin I analogues by PEM technology
MIC determination
Initial hits with broad spectrum antimicrobial activity and lack of hemolytic activity
Selective anti-Pseudomonas compounds with novel SAR
POL7001
LptD, a β-barrel outer membrane transporter is the target of POL7001 and POL7080
Efficacy studies in animal models of sepsis and respiratory infections
POL7080: preparations for a first Phase IIa clinical trial
under NABATIVI
Discovery Phase Approach B: “from drugs to targets”• Target identification runs in parallel to the discovery phase• Most antibiotics have been identified by this approach
POL7080
![Page 27: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/27.jpg)
27
NABATIVI scientific approach –Step 4: target identification running in parallel to the discovery phase
O
NH
NN
O
HO
HO
N
ON
N
H
H
O
H
NN
O
H O
H O
N
O
NH
N
O
H
N
Me
O
H O
N
H
N
O
NH
H3NH3N
HNH2N
H2N
NHH2N
H2N
H3N H3NH3N
NH
HO
LptD
Srinivas N, et al. Science. 2010Bragonzi A. Sci. Transl. Med. 2010
• LptD is an essential gene in P. aeruginosa and the target for novel drug POL7001 and POL7080
Polyphor Ltd.
University of Zurich
![Page 28: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/28.jpg)
28
NABATIVI scientific approach –Step 4: translational research up to clinical trial
POL7080
POL7001
Discovery phase Pre-IND Clinical phase
Polyphor Ltd.
San Raffaele Scientific Institute
• Novel drug POL7001 is active against MDR P. aeruginosa strains
• In pre-clinical studies including models of airway infections and septicemia, POL7001 showed higher efficacy when compared to clinically approved antibiotics
![Page 29: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/29.jpg)
29
POL7080 indications for P. aeruginosa infections
Indications for Pseudomonas infections
Urinary tract infectionsVentilator-associatedpneumonia (VAP)
Pseudomonas infectionin cystic fibrosis
(Mukoviscidosis)
![Page 30: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/30.jpg)
30
NABATIVI - Major achievements
Targetidentification
Libraryselection/design
Screeningcascade
Hitidentification Hit-to-lead
Leadoptimization
Discovery phaseA
Pre-clinicaldevelopment Phase I Phase II Phase III NDA Launch
Pre-clinical and clinical phasesB
A genomic target database of P. aeruginosa is assembled
Novel hits and PNAs are identified and are currently under validation
LptD as novel target for drug with novel mechanism of action is identified
POL7080 successfully completed Phase I and will start Phase II at the end of 2013
![Page 31: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/31.jpg)
31
NABATIVI – novel drug
![Page 32: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/32.jpg)
32
NABATIVI – hit the target !
![Page 33: NABATIVI – Novel Approaches to Bacterial Target Identification, Validation and Inhibition](https://reader036.fdocuments.in/reader036/viewer/2022062322/56814c47550346895db94c17/html5/thumbnails/33.jpg)
33
Critical success factors for NABATIVI project
• Integrated multidisciplinary research at European level was successful in novel drug discovery;
• Academia and a small innovative company worked together productively to fill the gap left by the migration of big pharmaceuticals away from antibacterial development;
• Combined scientific approaches, including exploitation of post-genomic information, were successful in identifying novel drugs;
• Optimal translation of the results into the clinic through appropriate pre-clinical models
Molecular microbiology
Genomics
Biochemistry
Structural biology
Cell biologyBioinformatics
Clinical research
High-throughput technology
Pre-clinical research Drugs